ES2186251T3 - Nuevos derivados de acilguanidina como inhibidores de la resorcion de los huesos y como antagonistas de receptores de vitronectina. - Google Patents
Nuevos derivados de acilguanidina como inhibidores de la resorcion de los huesos y como antagonistas de receptores de vitronectina.Info
- Publication number
- ES2186251T3 ES2186251T3 ES98966287T ES98966287T ES2186251T3 ES 2186251 T3 ES2186251 T3 ES 2186251T3 ES 98966287 T ES98966287 T ES 98966287T ES 98966287 T ES98966287 T ES 98966287T ES 2186251 T3 ES2186251 T3 ES 2186251T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- substituted
- aryl
- hydrogen
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
Un compuesto de la fórmula I:**Fórmula** en la que: R1 y R2 independientemente uno de otro son hidrógeno o alquilo de C1-C6, que no está sustituido o está sustituido con R3, con la condición de que R1 y R2 no sean ambos hidrógeno al mismo tiempo, o en la que: los radicales R1- y R2- son simultáneamente un radical alquileno de C2-C9 bivalente saturado o no saturado, que no está sustituido o está sustituido con uno o más grupos del grupo que comprende halógeno, alquilo de C1-C6, alcoxi de C1-C6, arilo de C6-C14, arilo de C6-C14-alquilo de C1-C6, heteroarilo de C5-C14, heteroarilo de C5-C14-alquilo de C1-C6, cicloalquilo de C3-C12, cicloalquilo de C3-C12-alquilo de C1-C6 y oxo, en la que un anillo saturado o insaturado de 5 miembros a 7 miembros, que no está sustituido o está sustituido con R3, y que es un anillo carbocíclico o un anillo heterocíclico que contiene uno o dos átomos de nitrógeno del anillo, puede estar condensado a un enlace carbono-carbono en el radical alquileno de C2-C9; R3 es alquilo de C1-C8, alcoxi de C1-C8, arilo de C5-C14, arilo de C5-C14-alquilo de C1-C4, halógeno, trifluorometilo, hidroxilo, nitro o amino; R4 es hidrógeno, alquilo de C1-C6-CO-O-alquilo de C1-C4, o alquilo de C1-C6, que no está sustituido o está sustituido con un radical del grupo que comprende hidroxilo, alcoxi de C1-C4, alquilo de C1-C4-S(O)2-, NR7R7'' y N+R7R7''R7''''Q- en el que R7, R7'' y R7" independientemente uno de otro son hidrógeno, alquilo de C1-C6, arilo de C5-C14 o arilo de C5-C14-alquilo de C1-C6, y Q- es un anión fisiológicamente tolerable, o en el que R4 es uno de los radicales **Fórmula** en los que los enlaces, por vía de los cuales están unidos los radicales, están representados por las líneas de trazos; R5 es alquilo de C1-C8, arilo de C6-C14-alquilo de C1-C6, o heteroarilo de C5-C14-alquilo de C1-C6, en el que el radical arilo o el radical heteroarilo no está sustituido o está sustituido con uno, dos o tres radicales R3; R6 es hidrógeno, alquilo de C1-C6-O-CO-, hidroxilo,alquilo de C1-C6-O-CO-O- o nitro; A es CH2, O, S o NH; m es 1, 2 ó 3; n es 0 ó 1; siendo el grupo heteroarilo un sistema de anillos aromáticos bicíclicos de 5 miembros a 14 miembros, que tienen 1 a 3 heteroátomos del grupo que comprende N, O o S, en todas sus formas estereoisómeras y sus mezclas en todas las proporciones, y sus sales fisiológicamente tolerables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97122520A EP0933367A1 (en) | 1997-12-19 | 1997-12-19 | Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2186251T3 true ES2186251T3 (es) | 2003-05-01 |
Family
ID=8227841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98966287T Expired - Lifetime ES2186251T3 (es) | 1997-12-19 | 1998-12-10 | Nuevos derivados de acilguanidina como inhibidores de la resorcion de los huesos y como antagonistas de receptores de vitronectina. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US6492356B1 (es) |
| EP (2) | EP0933367A1 (es) |
| JP (1) | JP2001526271A (es) |
| KR (1) | KR20010033281A (es) |
| CN (1) | CN1205191C (es) |
| AP (1) | AP2000001842A0 (es) |
| AR (1) | AR016437A1 (es) |
| AT (1) | ATE228112T1 (es) |
| AU (1) | AU753109B2 (es) |
| BG (1) | BG64754B1 (es) |
| BR (1) | BR9814308A (es) |
| CA (1) | CA2312712A1 (es) |
| CU (1) | CU23032A3 (es) |
| DE (1) | DE69809594T2 (es) |
| DK (1) | DK1042301T3 (es) |
| EA (1) | EA002921B1 (es) |
| ES (1) | ES2186251T3 (es) |
| HR (1) | HRP20000412A2 (es) |
| HU (1) | HUP0104912A3 (es) |
| ID (1) | ID26248A (es) |
| IL (1) | IL136858A0 (es) |
| MY (1) | MY122269A (es) |
| NO (1) | NO317420B1 (es) |
| NZ (1) | NZ504954A (es) |
| PL (1) | PL341216A1 (es) |
| PT (1) | PT1042301E (es) |
| SI (1) | SI1042301T1 (es) |
| SK (1) | SK9032000A3 (es) |
| TR (1) | TR200001964T2 (es) |
| TW (1) | TW446705B (es) |
| WO (1) | WO1999032457A1 (es) |
| YU (1) | YU39000A (es) |
| ZA (1) | ZA9811571B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6313119B1 (en) | 1998-01-23 | 2001-11-06 | Adventis Pharma Deutschland Gmbh | Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| WO2000006169A1 (en) * | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Integrin receptor antagonists |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| EP1028114A1 (en) * | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| EP1065207A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
| EP1070707A1 (en) | 1999-07-21 | 2001-01-24 | Aventis Pharma Deutschland GmbH | 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
| US6849639B2 (en) | 1999-12-14 | 2005-02-01 | Amgen Inc. | Integrin inhibitors and their methods of use |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| DE60130910T2 (de) | 2000-04-17 | 2008-07-10 | Ucb Pharma, S.A. | Enamin-derivate als zell-adhäsionsmoleküle |
| FR2808798A1 (fr) * | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | Nouveaux derives antagonistes du recepteur de la vitronectine |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| WO2002004426A1 (en) | 2000-07-07 | 2002-01-17 | Celltech R & D Limited | Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists |
| EP1176145A1 (en) * | 2000-07-28 | 2002-01-30 | Aventis Pharma Deutschland GmbH | Novel guanidino derivatives as inhibitors of cell adhesion |
| CA2417059A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R&D Limited | 3-substituted isoquinolin-1-yl derivatives |
| EP1197488A1 (en) * | 2000-10-10 | 2002-04-17 | Aventis Pharma Deutschland GmbH | (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use |
| FR2847254B1 (fr) * | 2002-11-19 | 2005-01-28 | Aventis Pharma Sa | Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant |
| FR2870541B1 (fr) * | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| FR2873585B1 (fr) * | 2004-07-27 | 2006-11-17 | Aventis Pharma Sa | Nouvelles formulations galeniques de principes actifs |
| US20060039949A1 (en) * | 2004-08-20 | 2006-02-23 | Nycz Jeffrey H | Acetabular cup with controlled release of an osteoinductive formulation |
| US20060057184A1 (en) * | 2004-09-16 | 2006-03-16 | Nycz Jeffrey H | Process to treat avascular necrosis (AVN) with osteoinductive materials |
| US9119901B2 (en) * | 2005-04-28 | 2015-09-01 | Warsaw Orthopedic, Inc. | Surface treatments for promoting selective tissue attachment to medical impants |
| US8414907B2 (en) | 2005-04-28 | 2013-04-09 | Warsaw Orthopedic, Inc. | Coatings on medical implants to guide soft tissue healing |
| US20070077267A1 (en) * | 2005-10-03 | 2007-04-05 | Sdgi Holdings, Inc. | Bioactive composite implants |
| US20070280986A1 (en) * | 2006-06-01 | 2007-12-06 | Carlos Gil | Intra-operative coating of implants |
| US8133553B2 (en) | 2007-06-18 | 2012-03-13 | Zimmer, Inc. | Process for forming a ceramic layer |
| US8309521B2 (en) | 2007-06-19 | 2012-11-13 | Zimmer, Inc. | Spacer with a coating thereon for use with an implant device |
| US8608049B2 (en) | 2007-10-10 | 2013-12-17 | Zimmer, Inc. | Method for bonding a tantalum structure to a cobalt-alloy substrate |
| WO2009096945A1 (en) * | 2008-01-29 | 2009-08-06 | Zimmer, Inc. | Implant device for use in an implant system |
| ES2864079T3 (es) | 2014-05-30 | 2021-10-13 | Pfizer | Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos |
| US11020160B2 (en) | 2016-03-21 | 2021-06-01 | Warsaw Orthopedic, Inc. | Surgical injection system and method |
| US10709814B2 (en) | 2016-04-22 | 2020-07-14 | Warsaw Orthopedic, Inc. | Osteoimplant comprising an insoluble fibrous polymer |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204350A (en) * | 1991-08-09 | 1993-04-20 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives |
| US5217994A (en) * | 1991-08-09 | 1993-06-08 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives |
| EP0667773A4 (en) * | 1992-10-14 | 1996-09-25 | Merck & Co Inc | FIBRINOGEN RECEPTOR ANTAGONISTS. |
| CA2150550A1 (en) * | 1992-12-01 | 1994-06-09 | Melissa S. Egbertson | Fibrinogen receptor antagonists |
| JP3895792B2 (ja) * | 1995-12-08 | 2007-03-22 | プロスケリア・エス・ア・エス | 骨形成促進剤 |
-
1997
- 1997-12-19 EP EP97122520A patent/EP0933367A1/en not_active Withdrawn
-
1998
- 1998-08-27 TW TW087110508A patent/TW446705B/zh not_active IP Right Cessation
- 1998-12-10 AP APAP/P/2000/001842A patent/AP2000001842A0/en unknown
- 1998-12-10 JP JP2000525394A patent/JP2001526271A/ja not_active Abandoned
- 1998-12-10 AT AT98966287T patent/ATE228112T1/de not_active IP Right Cessation
- 1998-12-10 EP EP98966287A patent/EP1042301B1/en not_active Expired - Lifetime
- 1998-12-10 HR HR20000412A patent/HRP20000412A2/hr not_active Application Discontinuation
- 1998-12-10 TR TR2000/01964T patent/TR200001964T2/xx unknown
- 1998-12-10 KR KR1020007006722A patent/KR20010033281A/ko not_active Ceased
- 1998-12-10 NZ NZ504954A patent/NZ504954A/en unknown
- 1998-12-10 CN CNB988136112A patent/CN1205191C/zh not_active Expired - Fee Related
- 1998-12-10 CA CA002312712A patent/CA2312712A1/en not_active Abandoned
- 1998-12-10 YU YU39000A patent/YU39000A/sh unknown
- 1998-12-10 SI SI9830345T patent/SI1042301T1/xx unknown
- 1998-12-10 US US09/581,915 patent/US6492356B1/en not_active Expired - Fee Related
- 1998-12-10 PL PL98341216A patent/PL341216A1/xx not_active Application Discontinuation
- 1998-12-10 BR BR9814308-5A patent/BR9814308A/pt not_active Application Discontinuation
- 1998-12-10 ES ES98966287T patent/ES2186251T3/es not_active Expired - Lifetime
- 1998-12-10 EA EA200000682A patent/EA002921B1/ru not_active IP Right Cessation
- 1998-12-10 SK SK903-2000A patent/SK9032000A3/sk unknown
- 1998-12-10 DK DK98966287T patent/DK1042301T3/da active
- 1998-12-10 IL IL13685898A patent/IL136858A0/xx not_active IP Right Cessation
- 1998-12-10 PT PT98966287T patent/PT1042301E/pt unknown
- 1998-12-10 ID IDW20001175A patent/ID26248A/id unknown
- 1998-12-10 CU CU20000149A patent/CU23032A3/es unknown
- 1998-12-10 DE DE69809594T patent/DE69809594T2/de not_active Expired - Fee Related
- 1998-12-10 WO PCT/EP1998/008051 patent/WO1999032457A1/en not_active Ceased
- 1998-12-10 AU AU22700/99A patent/AU753109B2/en not_active Ceased
- 1998-12-10 HU HU0104912A patent/HUP0104912A3/hu unknown
- 1998-12-17 AR ARP980106446A patent/AR016437A1/es unknown
- 1998-12-17 ZA ZA9811571A patent/ZA9811571B/xx unknown
- 1998-12-18 MY MYPI98005741A patent/MY122269A/en unknown
-
2000
- 2000-06-16 NO NO20003118A patent/NO317420B1/no unknown
- 2000-06-19 BG BG104544A patent/BG64754B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR016437A1 (es) | Derivados de acilguanidina como inhibidores de resorcion osea y como antagonistas del receptor vitronectina, procedimiento para su preparacion ypreparacion farmaceutica que los comprenden | |
| AR016001A1 (es) | Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente | |
| AR016762A1 (es) | Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo | |
| AR050267A1 (es) | Derivados de urea ciclicos sustituidos con heterociclo, su preparacion y su uso farmaceutico como inhibidores de quinasa | |
| BR0201697A (pt) | Compostos de alfa-aminoácid0, processo para a sua preparação e composições farmacêuticas contendo os mesmos | |
| BR0313160A (pt) | Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto | |
| AR035695A1 (es) | Compuestos inhibidores de metaloproteinasa, composicion farmaceutica, metodo de tratamiento, y uso de estos compuestos para la preparacion de medicamentos | |
| AR023707A1 (es) | Un derivado de pirrolidina, uso del mismo, procesos para la preparacion del mismo y una composicion farmaceutica que lo comprende | |
| AR050181A1 (es) | Derivados de urea ciclicos sustituidos, su preparacion y su uso farmaceutico como inhibidores de quinasa | |
| AR002012A1 (es) | Un compuesto, una composicion farmaceutica que lo comprende, su uso, metodo de tratamiento terapeutico, metodo para la preparacion del compuesto. | |
| PE20020566A1 (es) | DERIVADOS DE FENILACETAMIDO-PIRAZOLES COMO INHIBIDORES DE LA cdk/CICLINA QUINASA | |
| AR001787A1 (es) | Un compuesto oxazolidin sustituido particularmenteutil como inhibidor de calpaina y/o catepsina b e n el tratamiento de trastornos neurodegenerativos agudos o cronicos y composiciones farmacéuticas que incluyen dicho compuesto | |
| ES2189726T3 (es) | Isoxazolidinas sustituidas con heterociclo y su uso como fungicidas. | |
| ES2100302T3 (es) | Procedimiento para la fabricacion de composiciones de poliuretano cationico y sales de amonio cuaternario. | |
| BR0312560A (pt) | Novas espiropiperidinas ou espiropirrolidinas tricìclicas | |
| BRPI0008753B8 (pt) | composto de amida, processo para preparar um composto de amida, composição farmacêutica e uso de um composto de amida | |
| AR024837A1 (es) | Derivados de n-(iminometil)aminas, compuestos intermediarios para su preparacion, medicamento y composicion farmaceutica que los contienen y uso de dichos derivados para la produccion de medicamentos. | |
| AR040700A1 (es) | Derivados de pirimidilsulfonamida como moduladores de receptores de quimioquinas | |
| ES2113081T3 (es) | 1,4-benzotiazepinas utiles como agentes neurologicos. | |
| ES2061462T3 (es) | Compuestos cefemo, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
| AR043959A1 (es) | Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos | |
| ES2194683T3 (es) | Nuevos derivados siliciados de bencimidazol-benzazoles n-sustituidos o de bezofuranil-benzazoles filtros; composiciones cosmeticas fotoprotectoras que los contienen y utilizacion. | |
| AR033879A1 (es) | Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto | |
| BR0309558A (pt) | Derivados de quinazolina e medicamentos | |
| BR0308162A (pt) | Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso |